AbCellera's monthly antibody ABCL635 shows 83% symptom drop in menopause mid-stage study

AbCellera Biologics has put a new asset in front of investors and potential partners: ABCL635, an antibody injected under the skin once a month, which the company says sharply reduced the frequency of moderate-to-severe menopausal hot flashes in a Phase 2 trial. The results were disclosed in its third-quarter 2026 business update on 9 November.

At the 600 mg dose, patients on ABCL635 had 83% fewer vasomotor symptoms by week 4, against a 33% fall in the placebo arm, a gap of roughly 50 percentage points. AbCellera also said that no serious adverse events and no events of Grade 3 or above were recorded in treated patients, and that no liver or gastrointestinal signals emerged.

The commercial reading is necessarily cautious. The material available does not give the number of participants, the full dosing schedule, the statistical methods or a breakdown of adverse events, and the figures cover only four weeks. By way of context, rather than company data, approved non-hormonal options for these symptoms are generally taken as daily oral medicines, so a monthly injection would be a distinct proposition if the effect holds. AbCellera has not published pricing, a launch timeline or a view on positioning.

On regulation, the company says it is talking to authorities about next steps and is working through the US Food and Drug Administration's Model-Informed Drug Development programme, a pilot that lets sponsors discuss modelling and simulation approaches to development planning with the agency. AbCellera has not described what a pivotal programme would look like or when it might start.